Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Alzheimer’s Drugs Market: By Drug Class: Memantine, Cholinergic, Combined Drug, Others; By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Others; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Alzheimer’s Drugs Market Outlook

The global Alzheimer’s Drugs market is expected to grow at a CAGR of 6.8% during the period 2022-2027. The global market is expected to be driven by ageing global population and need for effective solutions to manage Alzheimer’s. It is reported that the number of cases of Alzheimer’s would nearly triple to 152.8 million by 2050. Significant regions include UAE, Qatar, USA, China, Germany, France, UK and Switzerland.

 

Global Market Likely to be Driven by Ageing Global Population and Need to Effectively Manage the Disease

Despite significant efforts towards developing a cure, Alzheimer’s remains incurable. However, there has been some progress in the fight against the condition. With the help of drugs, mental performance may be stabilized and progression of symptoms slowed. With medicinal treatment, several concomitant therapies are used today which seek to promote patients’ mental faculties or preserve those capabilities for as long as possible, enhancing overall quality of life and relieving the burden on relatives.

Alzheimer’s disease, named after the neurologist Alois Alzheimer, is the most common form of dementia, affecting nearly sixty to seventy percent of approximately 50 million dementia patients across the globe. It is a neurodegenerative disease (alongside Parkinson’s disease). The diseases are followed by a progressive loss of nerve cells and cell functions, which at one point of time becomes so great that it becomes impossible for the brain to compensate. The global Alzheimer’s drugs market is expected to be driven by ageing global population and the need for effective solutions to manage the disease. Depending on the stage (mild, moderate, severe), symptoms of the disease may include disorientation, memory loss, problems with speech, difficulty carrying out familiar activities, and changes in personality. These disorders may differ in severity, and increase as the disease progresses. Thus, everyday life becomes impossible to manage alone and the patient becomes increasingly dependent on support. This way, the quality of life of those affected and their relatives is considerably reduced.

 

Treatment Systems Helpful in Management of the Disease Expected to Boost Market Growth

A modern therapeutic procedure that has become available recently is Transcranial Pulse Stimulation (TPS®). TPS seeks to promote/maintain mental capabilities of people with Alzheimer’s disease, and is used to treat patients with mild to moderate Alzheimer’s. Acoustic pulses produced outside the body are introduced particularly into the brain regions needing treatment; treatment is administered on an outpatient basis. Such developments are likely to boost the global Alzheimer’s drugs market. TPS is safe and uncomplicated, with an average treatment duration of 30 minutes per session; one course of treatment entails six sessions over two weeks. TPS has been quite successful. In 2022, the 100th NEUROLITH® system was installed at the Lengg Clinic in Zurich, Switzerland.

While Alzheimer’s cannot be cured and its progression not stopped, through therapies and medicines, the progression of the disease may be slowed and symptoms alleviated. The aim of treatment is to decrease behavioural disorders and improve general patient well-being. In the early stages, a well-coordinated combination of therapeutic measures could significantly contribute to maintaining patient independence and quality of life.

Treatments available for the condition include Aducanumab/Aduhelm™, Donepezil/Aricept®, Galantamine/Razadyne®, Rivastigmine/Exelon®, Memantine/Namenda®, and Memantine + Donepezil/Namzaric®. Suvorexant/Belsomra® is used to treat non-cognitive symptoms (behavioral and psychological).

 

Market Segmentation

By drug class, the global Alzheimer’s drugs market is segmented into:

  • Memantine
  • Cholinergic
  • Combined Drug
  • Others

By distribution channel, the market is classified into:

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • Others

By region, the market is divided into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global Alzheimer’s drugs market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck Sharp & Dohme Corp.
  • Biogen Inc.
  • AbbVie Inc.
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Memantine
  • Cholinergic
  • Combined Drug
  • Others
Breakup by Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck Sharp & Dohme Corp.
  • Biogen Inc.
  • AbbVie Inc.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Alzheimer’s Drugs Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Alzheimer’s Drugs Historical Market (2017-2021) 
    8.3    Global Alzheimer’s Drugs Market Forecast (2022-2027)
    8.4    Global Alzheimer’s Drugs Market by Drug Class
        8.4.1    Memantine
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Cholinergic
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Combined Drug
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
        8.4.4    Others
    8.5    Global Alzheimer’s Drugs Market by Distribution Channel
        8.5.1    Retail Pharmacies
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Online Pharmacies
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Hospital Pharmacies
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Others
    8.6    Global Alzheimer’s Drugs Market by Region
        8.6.1    Market Share
            8.6.1.1    North America
            8.6.1.2    Europe
            8.6.1.3    Asia Pacific
            8.6.1.4    Latin America
            8.6.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    F. Hoffmann-La Roche Ltd
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Novartis AG
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Merck Sharp & Dohme Corp.
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Biogen Inc.
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    AbbVie Inc.
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Others
13    Industry Events and Developments

 

List of Key Figures and Tables

1.    Global Alzheimer’s Drugs Market: Key Industry Highlights, 2017 and 2021
2.    Global Alzheimer’s Drugs Historical Market: Breakup by Drug Class (USD Million), 2017-2021
3.    Global Alzheimer’s Drugs Market Forecast: Breakup by Drug Class (USD Million), 2022-2027
4.    Global Alzheimer’s Drugs Historical Market: Breakup by Distribution Channel (USD Million), 2017-2021
5.    Global Alzheimer’s Drugs Market Forecast: Breakup by Distribution Channel (USD Million), 2022-2027
6.    Global Alzheimer’s Drugs Historical Market: Breakup by Region (USD Million), 2017-2021
7.    Global Alzheimer’s Drugs Market Forecast: Breakup by Region (USD Million), 2022-2027
8.    North America Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
9.    North America Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
10.    Europe Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
11.    Europe Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
12.    Asia Pacific Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
13.    Asia Pacific Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
14.    Latin America Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
15.    Latin America Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
16.    Middle East and Africa Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2017-2021
17.    Middle East and Africa Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2022-2027
18.    Global Alzheimer’s Drugs Market Structure

Key Questions Answered in the Report

The market is projected to grow at a CAGR of 6.8% between 2022 and 2027.

The only disease-modifying drug currently approved to treat Alzheimer's is aducanumab. This treatment, which targets the protein beta-amyloid and works as an immunotherapy, helps to lessen amyloid plaques, which are brain lesions connected to Alzheimer's disease.

The major drivers of the global Alzheimer’s drugs market include the need for effective solutions to manage Alzheimer’s, development of digital tools, improving diagnostic capabilities, evolving healthcare infrastructure, and raising awareness regarding Alzheimer’s disease.

The ageing global population and growing cases of Alzheimer’s worldwide are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Based on drug class, the market is classified into memantine, cholinergic, and combined drug, among others.

The several distribution channels in the market are retail pharmacies, online pharmacies, and hospital pharmacies, among others.

Drugs including sertraline, fluoxetine, nortriptyline, citalopram (Celexa), and fluoxetine (Prozac) (Zoloft) keep Alzheimer's calm. Drowsiness, dry mouth, constipation, and anxiety are some of these medications' side effects.

The major players in the industry are F. Hoffmann-La Roche Ltd, Novartis AG, Merck Sharp & Dohme Corp., Biogen Inc., and AbbVie Inc., among others.

Purchase Full Report

Mini Report

$ 2199     $1799
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 3199     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$ 4199     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 5199     $4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER